The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens the company's position in the medical aesthetics market, AbbVie announced that its subsidiary Allergan Aesthetics received Health Canada's approval for Boey. The drug, scientifically known as trenibotulinumtoxinE, was approved for the temporary improvement of glabellar lines in adult patients. Boey is distinguished as the first neurotoxin serotype E featuring a rapid onset of action within just 8 hours and a short duration of 2 to 3 weeks.
Sign in to access this content
Sign InThis approval comes as the aesthetic treatment market sees rising demand for fast-acting solutions with shorter commitments, placing AbbVie in direct competition with traditional products like Botox and Dysport, which typically take days to show results. Per market data, the pharmaceutical sector is under pressure to innovate products that align with the preferences of younger consumers seeking flexibility. Canada serves as a significant secondary strategic market ahead of potential expansion into larger global jurisdictions.
Regarding market performance, ABBV stock stood at $216.63 (close June 18, 2026), trading between a low of $215.37 and a high of $222.3 during that session. Investors are now watching for similar regulatory updates from the U.S. FDA, which could serve as a more significant catalyst for the share price. Additionally, the upcoming economic calendar includes Canadian retail sales data which may impact regional consumer sentiment.